ISPOR - PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN) AS COMPARED WITH RANIBIZUMAB (LUCENTIS) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)

Full Text

PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN) AS COMPARED WITH RANIBIZUMAB (LUCENTIS) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)

Abstract

Authors

LY Lu W McGhan

Back to Volume 11, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now